(Q37801373)

23 August 2017

title

Medication adherence with disease modifying treatments for multiple sclerosis among US employees (English)

1 reference

23 August 2017

0 references

1

Nathan L Kleinman

1 reference

23 August 2017

Krithika Rajagopalan

3

1 reference

23 August 2017

Ian A. Beren

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20958113

5 August 2024

Richard A. Brook

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20958113

5 August 2024

language of work or name

English

0 references

publication date

19 October 2010

1 reference

full work available at URL

23 August 2017

https://www.tandfonline.com/doi/pdf/10.3111/13696998.2010.527588?needAccess=true

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20958113

http://www.informapharmascience.com/doi/abs/10.3111/13696998.2010.527588

5 August 2024

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20958113

http://www.tandfonline.com/doi/pdf/10.3111/13696998.2010.527588

5 August 2024

1 reference

https://api.crossref.org/works/10.3111/13696998.2010.527588

Journal of Medical Economics

5 August 2024

published in

1 reference

23 August 2017

volume

13

1 reference

23 August 2017

issue

4

1 reference

23 August 2017

page(s)

633-640

1 reference

Medscape journal of medicine

23 August 2017

cites work

2

10

225

Costello K

2008

1 reference

https://api.crossref.org/works/10.3111/13696998.2010.527588

International journal of MS care

5 August 2024

3

32

Cohen BA.

2006

1 reference

https://api.crossref.org/works/10.3111/13696998.2010.527588

A checklist for medication compliance and persistence studies using retrospective databases.

5 August 2024

4

1 reference

https://api.crossref.org/works/10.3111/13696998.2010.527588

The assessment of refill compliance using pharmacy records: methods, validity, and applications

5 August 2024

5

1 reference

https://api.crossref.org/works/10.3111/13696998.2010.527588

Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy

5 August 2024

6

1 reference

https://api.crossref.org/works/10.3111/13696998.2010.527588

Compliance, adherence, and the treatment of multiple sclerosis

5 August 2024

7

1 reference

https://api.crossref.org/works/10.3111/13696998.2010.527588

Measuring adherence and persistence to disease-modifying agents among patients with relapsing remitting multiple sclerosis

5 August 2024

8

1 reference

https://api.crossref.org/works/10.3111/13696998.2010.527588

Long-Term Adherence to Interferon β Therapy in Relapsing-Remitting Multiple Sclerosis

5 August 2024

9

1 reference

https://api.crossref.org/works/10.3111/13696998.2010.527588

Tolerability, adherence, and patient outcomes

5 August 2024

10

1 reference

https://api.crossref.org/works/10.3111/13696998.2010.527588

The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relapsing-remitting multiple sclerosis.

5 August 2024

11

1 reference

https://api.crossref.org/works/10.3111/13696998.2010.527588

Persistence and adherence to disease modifying drugs among patients with multiple sclerosis

5 August 2024

12

1 reference

https://api.crossref.org/works/10.3111/13696998.2010.527588

A prospective study of adherence to glatiramer acetate in individuals with multiple sclerosis

5 August 2024

13

1 reference

https://api.crossref.org/works/10.3111/13696998.2010.527588

5 August 2024

14

1 reference

https://api.crossref.org/works/10.3111/13696998.2010.527588

Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.

5 August 2024

15

1 reference

https://api.crossref.org/works/10.3111/13696998.2010.527588

Factors leading patients to discontinue multiple sclerosis therapies

5 August 2024

16

1 reference

https://api.crossref.org/works/10.3111/13696998.2010.527588

Injection anxiety remains a long-term barrier to medication adherence in multiple sclerosis

5 August 2024

17

1 reference

https://api.crossref.org/works/10.3111/13696998.2010.527588

Absenteeism and health-benefit costs among employees with MS.

5 August 2024

18

1 reference

https://api.crossref.org/works/10.3111/13696998.2010.527588

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

5 August 2024

19

1 reference

https://api.crossref.org/works/10.3111/13696998.2010.527588

The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France

5 August 2024

21

1 reference

https://api.crossref.org/works/10.3111/13696998.2010.527588

The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics

5 August 2024

22

1 reference

https://api.crossref.org/works/10.3111/13696998.2010.527588

Employer benefit design considerations for the era of biotech drugs

5 August 2024

23

1 reference

https://api.crossref.org/works/10.3111/13696998.2010.527588

5 August 2024

Identifiers

1 reference

23 August 2017

1 reference